Novo Nordisk A/S
Long

NVO – Long-Term Cycle View (5–7 Years)

370
Thesis
NVO is transitioning from a completed Cycle Wave 2 into a new multi-year expansion phase. The long-term bull structure remains intact, with fundamentals now acting as a catalyst for the next cycle leg.

Context
- Weekly timeframe
- Primary bull trend originates from the 2009 GFC low (< $1)
- Cycle Wave 1 completed in July 2024
- Deep corrective Cycle Wave 2 now appears complete

What I see
-Structural reversal underway from long-term trend support
- Price stabilizing in a major accumulation / buy zone
- New Wegovy pill acts as a fundamental trigger aligning with the technical reversal
- Momentum and structure support the start of Cycle Wave 3

What matters now
- Holding the current base keeps the Cycle Wave 3 thesis intact
- This phase is about accumulation, not timing short-term moves

Buy / Accumulation zone
- Current zone remains suitable for long-term positioning
- This is where multi-year risk/reward is defined

Targets
- Cycle Wave 3 (1.618 Fib): ~$273. Expected around early 2029. Approx. +450% from the buy area
- Cycle Wave 5: ~$415. Expected around 2033. Approx. +730% from the buy area

Income
- Dividend yield ~2.1% adds meaningful carry while holding

Conclusion
Strong technical cycle alignment + improving fundamentals make NVO a compelling long-term hold. This is a position built to be held through volatility, not traded.

คำจำกัดสิทธิ์ความรับผิดชอบ

ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมใน ข้อกำหนดการใช้งาน